Nektar Therapeutics

+$0.07 (+2.06%) Today

$0.00 (0.00%) As of 9:59 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.

About NKTR

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology.

CEO

Howard W. Robin

Employees

740

Headquarters

San Francisco, California

Founded

1990

NKTR Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

2.78M

High today

$3.50

Low today

$3.31

Open price

$3.40

Volume

3.83M

52 Week high

$19.37

52 Week low

$3.30

NKTR News

Simply Wall StMay 21

Have Insiders Sold Nektar Therapeutics Shares Recently? - Simply Wall St

Anyone interested in Nektar Therapeutics ( ) should probably be aware that the CEO, President & Director, Howard Robin, recently divested US$144k worth of share

Analyst ratings

Buy

7.7%

Hold

76.9%

Sell

15.4%

NKTR Earnings

-$0.81

-$0.54

-$0.27

$0.00

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 4, After Hours

Why Robinhood?

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. View more

Have Insiders Sold Nektar Therapeutics Shares Recently? - Simply Wall St

77%

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology.